• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Research and Markets: Restless Legs Syndrome - Recognition Lacking Still

Posted on: Wednesday, 2 February 2005, 12:00 CST

Research and Markets (http://www.researchandmarkets.com/reports/c12504) has announced the addition of Restless Legs Syndrome - Recognition Lacking Still to their offering

Although there are a huge number of individuals who report having the symptoms of RLS, this neurological disorder remains inadequately diagnosed and treated. There are plenty of opportunities in this market for pharmaceutical manufacturers, but raising awareness must be the first priority.

Despite affecting an estimated 66.6 million individuals, less than 10% of RLS sufferers receive treatment. If pharmaceutical companies are to see a return on their investment in this market, they must be willing to invest in raising awareness amongst the public and physicians. There is currently no treatment approved for RLS in the US and therapy typically involves 'off-label' use of a variety of drug classes. However, with GSK's Requip anticipated to become the first drug to gain approval for RLS in 2005, companies wishing to enter the market at a later date may have to implement more innovative strategies, such as targeting specific symptoms and patient cohorts.

Scope

-- Overview of the epidemiology and size of the RLS patient population

-- Examination of current clinical practice including professional involvement, clinical guidelines, and current treatment strategies

-- Evaluation of the market potential of key compounds, such as ropinirole and rotigotine, currently in development for restless legs syndrome

-- Assessment of key unmet needs in the restless legs market and strategies for addressing these

Highlights

-- Despite affecting an estimated 66.6 million individuals, less than 10% of RLS sufferers receive treatment. If market entrants plan to see a return on their investment, raising awareness amongst the public and physicians is key.

-- At present, there is no treatment approved for RLS in the US and therapy typically involves off-label use of a variety of drug classes. GSKs Requip is expected to be first to market during 2005 and will receive a significant boost to its revenues.

-- Companies entering the market after Requip may have to implement more innovative strategies, such as targeting specific symptoms and patient cohorts, if they are to gain support from regulatory bodies and physicians.

Reasons to Purchase

-- Assess the potential size of the restless legs syndrome patient population

-- Identify current therapies used for restless legs syndrome and the key unmet needs

-- Benchmark pipeline products against currently used therapies and assess future market potential

For more information visit http://www.researchandmarkets.com/reports/c12504

Source: Business Wire

More News in this Category